Floatz logo

Infigratinib

Refractory Malignant Solid Neoplasm

Sameek RoychowdhurySmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
81/ 100

Competitive context

181 Active assets in the Refractory Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB

View all 50 →

Same molecule, other indications

Infigratinib is also rated in:

GBMDormant
CCC
Indicative ·
54 / 100
View asset →
metastatic malignant neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →